Stem Cell Therapeutics Corp.

Presenter: Alan Moore, President & CEO

Company Information

Company Type: Therapeutics

Development Stage: Public

Company Profile

Stem Cell Therapeutics Corp. is a Canadian biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury.

Our lead program, NTx®-265, is a regimen of two approved and marketed drugs targeting the treatment of stroke. The therapy works by stimulating the growth and differentiation of new neurons to replace the brain cells that are lost or damaged by the stroke and importantly, to direct motor, visual and cognitive recovery after acute ischemic stroke. Our approach avoids surgical transplantation of stem cells; instead we use drugs to stimulate the body's own existing adult stem cells.

Contact

Stem Cell Therapeutics Corp.
Suite 1000 1520 - 4th Street SW
Calgary
Alberta, Canada
T2R 1H5

ph: 1-403-245-5495x224
fx: 1-403-245-5411

www.stemcellthera.com
amoore@stemcellthera.com